Auroempa L 25/5MG Tab

Composition

Empagliflozin 25 mg + Linagliptin 5 mg tablet

Uses of Auroempa L 25/5MG Tab

Type 2 diabetes mellitus: adjunct to diet and exercise to improve glycaemic control in adults when dual therapy is appropriate (including patients inadequately controlled on either component).

• •Lowers HbA1c and fasting/postprandial glucose
• •Once-daily dual therapy for type 2 diabetes
• •Low intrinsic risk of hypoglycaemia (unless with insulin/SU)
• •May aid modest weight reduction and lower blood pressure (empagliflozin component)

How it works

Empagliflozin is an SGLT2 inhibitor that lowers blood sugar by increasing urinary glucose excretion via the kidneys. Linagliptin is a DPP-4 inhibitor that increases incretin hormones, enhancing insulin release and reducing glucagon secretion in a glucose-dependent manner.

Directions for use

Oral tablet. Usually taken once daily, with or without food, at the same time each day. Swallow whole with water; do not crush unless advised. Dose and duration as prescribed by a doctor; continue diet/exercise and regular glucose monitoring.

Side effects

Common side effects of Auroempa L 25/5MG Tab may include:

• •Increased urination
• •thirst
• •genital fungal infection
• •urinary tract infection